Corcept Therapeutics Incorporated is named one of the 11 Best Long Term Low Risk Stocks to Invest in. The company completes a key drug study and submits a new drug application to the U.S. FDA. Analysts maintain a Buy rating with price targets of $131 and $145. Corcept offers low-risk, high-growth potential with a beta of 0.20 and projected EPS growth of 69.48%.

Read more at Yahoo Finance: Corcept Therapeutics Advances Pipeline Fueling Growth With Controlled Risk